Press Releases

Press Releases

Sep 19, 2023
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 06, 2023
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
Aug 09, 2023
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Jun 08, 2023
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
Jun 07, 2023
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
Jun 06, 2023
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
Jun 02, 2023
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
May 22, 2023
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2023
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Apr 28, 2023
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
Displaying 1 - 10 of 15
Media & IR Contact
Investor Contact

Robin Garner
Investor Relations
Contact Us

Media Contact

David Rosen
Argot Partners
[email protected]

Helpful Tools